Selected Grants
TAK-573-1501
Clinical TrialPrincipal Investigator · Awarded by Takeda Development Center Americas, Inc · 2022 - 2027Duke ACS Institutional Research Grant
ResearchSignificant Contributor · Awarded by American Cancer Society, Inc. · 2024 - 2026Hematology & Transfusion Medicine (T32)
Inst. Training Prgm or CMEPreceptor · Awarded by National Institutes of Health · 1975 - 2026Targeting convergent oncogenic signaling during AR inhibition to overcome metastasis and immune evasion in prostate cancer
ResearchCo Investigator · Awarded by National Institutes of Health · 2019 - 2025Role of SLAMF7 in Racial Disparities in Myeloma
ResearchPrincipal Investigator · Awarded by National Cancer Institute · 2023 - 2025TAK-573-1501
Clinical TrialPrincipal Investigator · Awarded by Takeda Development Center Americas, Inc · 2022 - 2027Duke ACS Institutional Research Grant
ResearchSignificant Contributor · Awarded by American Cancer Society, Inc. · 2024 - 2026Hematology & Transfusion Medicine (T32)
Inst. Training Prgm or CMEPreceptor · Awarded by National Institutes of Health · 1975 - 2026Targeting convergent oncogenic signaling during AR inhibition to overcome metastasis and immune evasion in prostate cancer
ResearchCo Investigator · Awarded by National Institutes of Health · 2019 - 2025Role of SLAMF7 in Racial Disparities in Myeloma
ResearchPrincipal Investigator · Awarded by National Cancer Institute · 2023 - 2025Investigating the Role of a Novel Dendritic Cell Subset within Sentinel Lymph Node Tissues in Immune Evasion and Melanomagenesis
ResearchCollaborator · Awarded by Department of Defense · 2021 - 2024Role of Tumor-mediated Innate Training in the Pathogenesis of Immune-related Adverse Events
ResearchCollaborator · Awarded by Cancer Research Institute · 2022 - 2024Investigation of T-cell fitness and mechanisms of drug resistance in selinexor treated patients with relapsed/refractory multiple myeloma
ResearchPrincipal Investigator · Awarded by Karyopharm Therapeutics · 2023 - 2024R21 Enhancing CAR T therapy in multiple myeloma
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2022 - 2024A Precision Oncology Micro-Organosphere-Based Platform to Guide Multiple Myeloma Therapy
ResearchPrincipal Investigator · Awarded by Xilis, Inc. · 2022 - 2023Thioredoxin, a novel agent for mitigating radiation-induced hematopoietic injury
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2022 - 2023Epigenomic Reprogramming in Patient Derived Models of Colorectal Cancer
ResearchCo Investigator · Awarded by National Institutes of Health · 2018 - 2023THIOREDOXIN REGULATES P53 TRANSCRIPTION IN HEMATOPOIETIC STEM CELLS
ResearchPrincipal Investigator · Awarded by American Society of Hematology · 2022 - 2023Targeting the p38/Snail/PD-L1 axis in hormone-therapy resistance and metastasis
ResearchCo Investigator · Awarded by Department of Defense · 2018 - 2022A PHASE 2, MULTICENTER, MULTI-COHORT, OPEN-LABEL STUDY OF POMALIDOMIDE IN COMBINATION WITH LOW-DOSE DEXAMETHASONE OR POMALIDOMIDE IN COMBINATION WITH LOW-DOSE DEXAMETHASONE AND DARATUMUMAB IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA
Clinical TrialPrincipal Investigator · Awarded by Celgene Corporation · 2017 - 2022Effects of PPAR agonists on response to immunomodulatory agents in patients with multiple myeloma
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2019 - 2021Phase I study of Pomolidomide, Bortezomib, and Dexamethasone (PVD) as First-Line treatment of AL Amyloidosis or Light Chain Deposition Disease
Clinical TrialPrincipal Investigator · Awarded by Karmanos Cancer Center · 2014 - 2021Targeting sphingosine kinase 2 for the treatment of multiple myeloma
Clinical TrialPrincipal Investigator · Awarded by National Institutes of Health · 2015 - 2021Clinical characteristics, JAK2 status, and macrophage infiltration in multiple myeloma patients with marrow fibrosis
ResearchPrincipal Investigator · Awarded by Incyte Corporation · 2017 - 2020Clinical Trial of ABC294640 in Patients with Refractory Multiple Myeloma
ResearchPrincipal Investigator · Awarded by Apogee Biotechnology Corporation · 2015 - 2019Ph III study to evaluate the safety of ALN-TTR02 in TTR-Medicated Polyneuropathy
Clinical TrialPrincipal Investigator · Awarded by Alnylam Pharmaceuticals · 2014 - 2018Thioredoxin for radioprotection
ResearchPrincipal Investigator · Awarded by Columbia University · 2016 - 2018Develop and Support of the RedCap database, bio-statistic analysis, and med writing for Dr Kang NIH SBIR award Clin Trial
ResearchPrincipal Investigator · Awarded by RedHill Biopharma Ltd. · 2016 - 2018Plerixafor for allogeneic hematopoietic stem cell transplantation
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2014 - 2016External Relationships
- American Association for Cancer Research
- Blue Bird
- OrPro Therapeutics Inc
- PSI Pharma Support American Inc
- Sanofi
- American Association for Cancer Research
- Blue Bird
- OrPro Therapeutics Inc
- PSI Pharma Support American Inc
- Sanofi
- Xilis, Inc
This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.